A unique feature of the tumor cells (Hodgkin/Reed-Sternberg (HRS)) of classical Hodgkin lymphoma (cHL) is the loss of their B-cell phenotype despite their B-cell origin. Several lines of evidence suggest that epigenomic events, especially promoter DNA methylation, are involved in this silencing of many B-cellassociated genes. Here, we show that DNA demethylation alone or in conjunction with histone acetylation is not able to reconstitute the B-cell-gene expression program in cultured HRS cells. Instead, combined DNA demethylation and histone acetylation of B-cell lines induce an almost complete extinction of their B-cell-expression program and a tremendous upregulation of numerous Hodgkin-characteristic genes, including key players such as Id2 known to be involved in the suppression of the B-cell phenotype. Since the upregulation of Hodgkincharacteristic genes and the extinction of the B-cell-expression program occurred simultaneously, epigenetic changes may also be responsible for the malignant transformation of cHL. The epigenetic upregulation of Hodgkin-characteristic genes thus playsFin addition to promoter DNA hypermethylation of B-cellassociated genesFa pivotal role for the reprogramming of HRS cells and explains why DNA demethylation alone is unable to reconstitute the B-cell-expression program in HRS cells.
Introduction
Classical Hodgkin lymphoma (cHL) represents a lymphoid neoplasm, whose tumor cells, that is the Hodgkin and ReedSternberg (HRS) cells, are derived from germinal center B cells in almost all instances. [1] [2] [3] Despite their genotypical B-cell nature, the HRS cells are unable to express a normal B-cell phenotype 2,4-6 and it was suggested that an aberrant DNA hypermethylation status is responsible for this extinction. 7, 8 Recently, we collaboratively unveiled an alternative mechanism for the disturbance of the B-cell-expression program in HRS cells. 9 We demonstrated that two B-cell-inappropriate genes namely Id2 and ABF-1, whose helix-loop-helix products antagonize the function of the B-cell-determining transcription factor E2A, are overexpressed in HRS cells. Functional studies proved that an inhibition of E2A by transfection of Id2 and ABF-1 in B-cell lines results in a reduced expression of B-cell-specific genes. This inhibitory mechanism also appears to be active in primary HRS cells. 9 However, the reason for the non-physiological upregulation of Id2 and ABF-1 may be manifold. 10 We hypothesized that the upregulation of Id2 and ABF-1 and other B-cell-inappropriate genes in HRS cells might be related to epigenetic alterations. Therefore, we decided to investigate whether the expression of B-cell-inappropriate genes, including those that antagonize the function of E2A, can be induced by DNA demethylation alone or in conjunction with histone acetylation in B-cell lines. For this purpose, we treated B-cell lines exhibiting a full B-cellexpression program, and for comparison Hodgkin cell lines, with 5-aza-deoxy-cytidine (5-aza-dC) alone or in combination with the histone deacetylase inhibitor trichostatin A (TSA). The results obtained show that DNA demethylation of Hodgkin cell lines does not restore the B-cell phenotype, but that combined DNA demethylation and histone acetylation of Burkitt lymphoma and diffuse large B-cell lymphoma cell lines induces a Hodgkin-like gene expression program in these B cell lines.
Materials and methods

Cell culture
Cell lines were cultured in RPMI 1640 supplemented with 10% fetal bovine serum at 37 1C and 5% CO 2 .
5-aza-dC treatment
Since different 5-aza-dC concentrations and incubation times have been previously described, we treated the Hodgkin derived cell lines L428, KMH2 and L1236 with 5-aza-dC (SigmaAldrich, St Louis, MO, USA) at a concentration of 5 mM for 5 days with drug and medium replacement after each 48 h, and alternatively with 1 mM 5-aza-dC for 24 h. 8 
Combined 5-aza-dC/TSA treatment
The Burkitt-lymphoma-derived cell lines (Daudi, Namalwa and Raji) and diffuse large B-cell lymphoma derived cell lines (SU-DHL-4 and SU-DHL-6) were treated with 5-aza-dC at a concentration of 3 mM for 6 days. 5-aza-dC and medium were replaced at days 2 and 5. On day 5Fin addition to 3 mM 5-aza-dCFcells were incubated for 24 h with 625 nM TSA (Sigma-Aldrich). Cells were harvested on day 6. All experiments were repeated at least three times.
RNA Isolation
Total RNA was isolated from untreated and treated cells using the RNeasy Mini or Midi Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. For real-time RT-PCR, total RNA was treated with DNase for 15 min at room temperature. The quality of the RNA was controlled using the BioAnalyzer (Agilent, Santa Clara, CA, USA) and exclusively high quality RNA was used for further analysis. 
Western blot
Microarray analysis
Affymetrix GeneChip hybridization (HG-U133A) was performed with 5 mg total RNA according to the manufacturer's recommendations. Two independent experiments were hybridized in duplicates. The microarray data are available from the Gene Expression Omnibus of the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov/geo/) through the GEO accession number GSE8388.
Microarray data analysis
Analysis of microarray data ( Figure 2 ) was carried out using the statistical programming environment R together with software from the Bioconductor project. Probe intensities were normalized according to a variance-stabilization method. Gene expression levels were estimated by fitting an additive model according to Irizarry et al. 11 Analysis was restricted to a predefined set of 69 genes known to be up-or downregulated in HRS cells compared to B cells. 12 Corresponding HG-U133A probe sets were identified using Entrez Gene identifiers. 13 To determine lists of differentially expressed genes, we performed a gene-by-gene analysis using the method of Smyth et al.
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Q-values were estimated from P-values according to Benjamini and Hochberg. 15 
Real-time RT-PCR
TaqMan Reverse Transcription Reagents (Applied Biosystems, Foster City, CA, USA) were used to transcribe DNase I-digested total RNA in cDNA with random hexamer primers. Real-time PCR was performed with SYBR Green PCR-Master Mix (Applied Biosystems) on a GeneAmp7000 sequence detection system (Applied Biosystems) using the PCR parameters recommended by the manufacturer. The housekeeping gene succinate dehydrogenase complex, subunit A was amplified in parallel with each gene of interest. Relative mRNA quantification was calculated using the comparative DDC T method. Primer sequences are available from Supplementary Table S2 .
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) experiments were performed as described in detail in the Supplementary data (Supplementary protocols S1 and S2). Immunoprecipitation was carried out with an anti-acetyl-histone H3 antibody (H3-K9/K14, 06-599; Upstate, Temecula, CA, USA) or anti-5-methyl cytidine antibody (MAb-5MECYT-100; Diagenode, Liége, Belgium). Successful enrichment of immunoprecipitated DNA was confirmed by real-time DNA-PCR by comparison with the negative control (input DNA). In addition, the second exon of the PAX5 gene located more than 13 000 bp downstream of the start codon was amplified as a reference. Primer sequences are available from Supplementary Table S3 .
Results
Global DNA demethylation alone or in combination with histone acetylation is unable to restore the B-cell phenotype of Hodgkin cell lines DNA demethylation of Hodgkin cell lines by 5-aza-dC induces transcriptional effects as demonstrated by Affymetrix GeneChip analysis and more than 30% of the identified probe sets represent genes, which are known to be directly regulated by DNA methylation (Supplementary Table S4 , column E). However, a significant reactivation of B-cell-specific/characteristic genes was not detectable.
The 
Combined global DNA demethylation and histone acetylation of B-cell lines results in a Hodgkin-like phenotype
In contrast to Hodgkin cell lines, the combined 5-aza-dC and TSA treatment of B-cell lines resulted in a dramatic effect on the B-cell phenotype leading to the complete extinction of the B-cell-expression program. Simultaneously, several Hodgkincharacteristic genes were strongly upregulated ( Figure 2 ). This treatment-induced epigenetic up-and downregulation of genes demonstrated a striking overlap with genes known to be differentially expressed between B-cell and Hodgkin cell lines (for example more than 50% overlap with the genes identified by Kü ppers et al.
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). Further global transcriptional changes comprise many genes published to be directly regulated by epigenetic mechanisms (approx 20% of the identified probe sets with a fold change 43, Supplementary Table S5 , column E). Interestingly, the downregulation of B-cell-related genes and upregulation of Hodgkin-characteristic genes was less pronounced when 5-aza-dC or TSA were applied separately (Supplementary Figure S2) .
The almost complete extinction of the B-cell identity including numerous transcriptional regulators as well as tyrosine kinases was confirmed at the RNA and protein level ( Figure 3 and Supplementary Figure S3 ). This confirmation of the GeneChip data also holds true for the upregulation of numerous Hodgkin-characteristic genes ( Figure 4 and Supplementary Figure S4 ).
Promoter histone acetylation and DNA methylation status of B-cell-specific and Hodkin-characteristic genes To demonstrate that the induction of the Hodgkin-like phenotype in B-cell lines is caused by treatment-induced epigenetic changes we performed a H3-acetylation and methylation ChIP analyses before and after treatment with 5-aza-dC and TSA. As expected, the treatment induced an increased promoter histone acetylation and/or decreased promoter DNA methylation of all analyzed Hodgkin-characteristic genes (TIMP1, RANTES (CCL5), MUM1 (IRF4), Fascin, Syndecan 4 and IPL (TSSC3/PHLDA2) ( Figure 7 ). These treatment-induced epigenetic modifications of the promoter of the analyzed genes are well in line with the corresponding expression changes as demonstrated at the RNA and protein levels.
Discussion
Classical Hodgkin lymphoma representsFaccording to its cellular originFa germinal center B-cell lymphoma. However, in contrast to germinal center B-cell lymphomas of non-Hodgkin type, the HRS cells have lost most of the gene expression program specific to germinal center B cells. 4, 5 Currently, there are two main hypotheses to explain this phenomenon: (i) promoter DNA hypermethylation of B-cell genes inhibits the binding of B-cell-specific transcription factors and is thus solely or mainly responsible for silencing the B-cell genes 7, 8 and (ii) overexpression of the helix-loop-helix proteins Id2 and ABF-1 causes repression of the B-cell genes by inhibiting the B-celldetermining transcription factor E2A. 9 We conducted a comprehensive experimental approach to clarify which of these hypotheses is correct. First, we subjected Hodgkin cell lines to the demethylating agent 5-aza-dC. A significant reactivation of the B-cell-gene expression program was not inducible in Hodgkin cell lines. This finding appears to be in contrast to previously published data raised by nonquantitative mRNA measurements, which described a reconstitution of the B-cell phenotype after demethylation of Hodgkin cell line cells. 7, 8 However, our quantification by real-time RT-PCR clearly demonstrates that the impact of this treatment on the expression of B-cell genes is very weak, by far not reaching the expression level of these genes in B cells. This finding is further supported by our data obtained by protein analysis, which virtually excluded a reactivation of B-cell-characteristic antigens.
Since acetylation can act synergistically in conjunction with demethylation, 16, 17 we exposed the Hodgkin cell line cells not only to 5-aza-dC, but also to the histone deacetylase inhibitor TSA. Even this combined treatment was unable to significantly reactivate the expression of B-cell genes in the cultured HRS cells (data not shown). These results provide evidence that promoter DNA methylation neither alone nor in combination with histone-deacetylation is the sole cause for the downregulation of the B-cell program in cHL.
The second hypothesis namely the suppression of the B-cell phenotype in cHL by overexpression of negative regulators such as Id2 and/or ABF-1 9 implies that these negative regulators are suppressed in normal B cells. The absence of these negative regulators allows probably a B-cell differentiation and maintenance of the complete B-cell phenotype. To elucidate whether Id2 and/or ABF-1 are silenced in normal B cells by epigenetic mechanisms, we subjected several B-cell lines exhibiting the full B-cell phenotype to 5-aza-dC and/or TSA treatment. The combined 5-aza-dC and TSA treatment had a great impact on the gene expression profile of B-cell lines and, as expected, the vast majority of the reactivated genes are known to be directly regulated by DNA methylation and/or histone acetylation (see references in Supplementary Table S5 , column E). Most of these global effects are cell-type independent.
Unexpectedly, the treatment of the B-cell lines resulted in addition to the cell-type independent expression changes to a tremendous downregulation of virtually all B-cell-characteristic genes and a selective upregulation of Hodgkin-characteristic genes ( Figures 2-4 and Supplementary Figures S3 and S4) . Interestingly, the upregulation includes transcriptional regulators such as Id2, Notch1, MUM1 (IRF4), TCF7 (TCF1) and ATF3, which are typically expressed in cHL. 9, [18] [19] [20] The upregulation of Id2, TCF7 (TCF1) and Notch1 in B-cell lines after combined demethylation and acetylation is of special interest since it has already been shown that they are involved in the extinction of Bcell-specific/characteristic genes or prevention of B-lineage commitment. 9, 21, 22 Our results imply that the high expression of these genes in cHL is induced by epigenetic mechanisms finally leading to the extinction of the B-cell-expression program.
The epigenetic impact on the gene expression profile of B-cell and Hodgkin cell lines is supported by our histone acetylation and DNA methylation analysis of several genes characteristic for cHL and for B cells, respectively. The promoters of the analyzed Hodgkin-characteristic genes were found to be not acetylated (Figure 5b and Supplementary Figure S5B ), but methylated ( Figure 6 ) in B-cell lines whereas the opposite situation is encountered in Hodgkin cell lines. In contrast, the B-cell-specific genes are acetylated (Figure 5a and Supplementary Figure S5A ) but not methylated in B-cell lines ( Figure 6 ) and vice versa in Hodgkin cell lines. As demonstrated by H3-acetylation and DNA methylation ChIP experiments, before and after 5-aza-dC/TSA treatment, the expression changes of the analyzed genes are indeed caused by treatment-induced epigenetic modifications of the promoter of the corresponding genes. Thus, combined 5-aza-dC/TSA treatment is able to push the B-cell-expression profile of the B-cell lines toward an expression profile highly typical for Hodgkin cells. The observation of methylated B-cell genes in Hodgkin cells is in harmony with the previous investigations 7, 8 demonstrating promoter hypermethylation of SYK, C79b and POU2AF1 (Bob1) in Hodgkin cells, whereas these promoters were found to be not methylated in B cells. Here, we describe for the first time that the opposite holds true for the promoter of Hodgkin-characteristic genes, which are demethylated and/or acetylated in Hodgkin cells but methylated and/or not acetylated in B-cell lines, a scenario being able to fully explain the paradox phenotype of HRS cells.
The unravelling of these fascinating coherences reveals an important tessera, which points toward a close association between the loss of the B-cell identity and the transforming event giving rise to cHL. This transforming event most likely takes place in the course of the germinal center reaction. This conclusion is derived from the observation of patients in whom cHL and follicular lymphoma simultaneously or subsequently occur. 23, 24 Although both lymphoma entities originated from the same mature precursor B cell, as demonstrated by the same immunoglobulin gene rearrangement and by partially identical somatic hypermutations, their expression profiles differed completely. Whereas the follicular lymphoma fully maintained its germinal center B-cell phenotype, the coexisting cHL had completely lost the germinal center B-cell identity. 23, 24 This scenario suggests that the transforming event is composed not of many but only few steps, which probably occur in a relative short time frame. This conclusion supports the view that the transforming event leading to cHL is caused by a global epigenetic modification, which has the capacity to induce a transcriptional avalanche effect with rapid and extensive changes in the B-cell-expression program.
Conclusion
Taken together, our data show that DNA demethylation and histone acetylation induce in B cells a Hodgkin-like phenotype, whereas in Hodgkin cells no reactivation of B-cell-typical genes or suppression of B-cell-inappropriate genes was observed by this treatment. This finding suggests that the same genes, which can be turned on in B cells by DNA demethylation and histone acetylation are constitutively active in Hodgkin cells. The next goal is to identify and characterize these genes, since they are highly likely to be responsible for the downregulation of the B-cell program and upregulation of Hodgkin-characteristic genes. It might well be that these genes are also involved in the oncogenic process leading to Hodgkin lymphoma. 
